Developing an AI tool to quickly identify high-performing cells for drug development
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
This study is testing a new AI tool that helps scientists quickly find the best cells for making important medicines, which could speed up the process of developing new treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanocellect Biomedical, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10672364 on NIH RePORTER |
What this research studies
This research focuses on creating an innovative tool that utilizes artificial intelligence to identify and isolate high-performing cells crucial for the development of monoclonal antibodies. By employing advanced imaging techniques and AI algorithms, the tool aims to predict cell growth characteristics immediately after genetic modification. This approach significantly reduces the time required for clone selection from weeks to just a few days, while also increasing the number of valuable clones that can be analyzed. The ultimate goal is to enhance the efficiency of drug development processes, particularly for protein-based therapeutics.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals involved in the development of monoclonal antibodies or those requiring advanced therapeutic options.
Not a fit: Patients who are not involved in monoclonal antibody treatments or do not require protein-based therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more efficient development of life-saving monoclonal antibody treatments.
How similar studies have performed: Other research has shown success with AI applications in drug development, indicating that this approach has the potential for significant advancements.
Where this research is happening
San Diego, United States
- Nanocellect Biomedical, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Cho, Sung Hwan — Nanocellect Biomedical, INC.
- Study coordinator: Cho, Sung Hwan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.